Rieter (RIEN) investor relations material

Executive summary

• 9M order intake was CHF 951.4m, up 70.1% reported but down 10.5% organically; sales were CHF 898.6m, up 96.3% reported but down 2.1% organically, largely reflecting Barmag consolidation.

• Q3 order intake was CHF 397.3m and sales were CHF 321.9m; backlog stood at ~CHF 850m at September 30, 2026.

• FY2026 sales are expected at the lower end of CHF 1.3bn–1.5bn, with operating EBIT margin of -2% to 0%.

Financial highlights

• 9M order intake was CHF 951.4m versus CHF 559.3m; reported growth of 70.1% included an 84.3% M&A impact and -3.7% FX impact, while organic intake declined 10.5%.

• 9M sales were CHF 898.6m versus CHF 457.7m; reported growth of 96.3% included a 102.0% M&A impact and -3.6% FX impact, while organic sales declined 2.1%.

• Quarterly order intake rose from CHF 226m in Q1 to CHF 328m in Q2 and CHF 397.3m in Q3; 9M book-to-bill exceeded 1x.

• 9M sales mix comprised CHF 645.5m from new machines and equipment and CHF 253.1m from installed base and components.

Outlook and guidance

• FY2026 sales are expected at the lower end of the prior CHF 1.3bn–1.5bn range; operating EBIT margin guidance is -2% to 0%.

• Q4 guidance depends on execution and shipment timing of large orders; typical order-to-sales lead times are six to 12 months.

• Backlog was ~CHF 850m; most Q4 deliveries are expected from existing backlog, with remaining orders predominantly for 2027 and some Man-Made Fiber projects extending further.

• No substantial market recovery is expected in 2027 at this point; visibility is six to nine months. Restructuring benefits are expected to be fully visible in 2028.